Glycogen Synthase Kinase 3: A Point of Integration in Alzheimer's Disease and a Therapeutic Target? | Zendy

Siddhartha MondragónRodríguez | Zendy; George Perry | Zendy; Xiongwei Zhu | Zendy; Paula I. Moreira | Zendy; Sylvain Williams | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glycogen Synthase Kinase 3: A Point of Integration in Alzheimer's Disease and a Therapeutic Target?

Author(s) -

Siddhartha MondragónRodríguez,

George Perry,

Xiongwei Zhu,

Paula I. Moreira,

Sylvain Williams

Publication year - 2012

Publication title -

international journal of alzheimer s disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.657

H-Index - 49

eISSN - 2090-8024

pISSN - 2090-0252

DOI - 10.1155/2012/276803

Subject(s) - gsk 3 , neuroscience , glycogen synthase , synaptic plasticity , gsk3b , medicine , disease , therapeutic approach , bioinformatics , kinase , glycogen , biology , microbiology and biotechnology , receptor

Glycogen synthase kinase 3 (GSK3) has been implicated in neurological disorders; therefore, it is not surprising that there has been an increased focus towards developing therapies directed to this kinase. Unfortunately, these current therapies have not taken into consideration the physiological role of GSK3 in crucial events like synaptic plasticity. With this in mind we will discuss the relationship of synaptic plasticity with GSK3 and tau protein and their role as potential targets for the development of therapeutic strategies. Finally, we will provide perspectives in developing a cocktail therapy for Alzheimer's treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research